Lamiae directs the part of the company that performs real-world studies. Lamiae is one of the founders of the famous PGRx information system. She has over 12 years’ experience in clinical pharmacology (board-certified) and pharmacoepidemiology (PhD), notably in the conduct of real-world studies.

Specializing in methodological development as directly applicable to real-world studies, her experience includes the design, conduct, and analysis of major, landmark studies. She has the unique experience of both primary data collection from physicians and patients and of the analysis of electronic health care databases. Lamiae has conducted over 20 major studies involving clinical, patient-reported, and functional outcomes assessment internationally and an additional dozen studies using eHCD or EMR, and numerous surveys.

At the request of clients, she is often designated as the principal investigator of their studies and she has presented her work at local, national, and international conferences as the director and principal investigator of the PGRx® database and information system (Pharmacoepidemiological General Research eXtension), the first database conceived for pharmacoepidemiology and drug assessment purposes. She is part of the PROTECT program (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) coordinated by The European Medicines Agency (EMA).

Before joining LASER in 2006, Lamiae established a clinical and academic career as chief resident in clinical pharmacology at a University Hospital in France where she ran the regional pharmacovigilance unit. She is now an Associate professor at the Conservatoire National des Arts & Métiers where she directs a Masters Program on Drug Evaluation, Market Access & Public Health and is a Fellow of the Pasteur Institute.